Protocol summary

Study aim
Comparison of intrathecal injection of fentanyl and sufentanil along with bupivacaine in onset, duration and quality of painless labor.
Design
A double-blind, randomized clinical trial with parallel groups design of 80 patients.
Settings and conduct
This study is conducted in Alzahra Hospital in Rasht. After explaining the purpose and method of the research, informed consent will be obtained. Pregnant mothers will be carefully placed in a sitting position.In sterile conditions, a 25-size needle will be entered into the intraspinal space through lumbar vertebrae L3-L4 or L4-L5, and the injection will be performed.Pulse oximetry, blood pressure and electrocardiography will be evaluated continuously until the end of the operation. The sensory and motor block will be continuously monitored after injection.The pain score for labor analgesia will also be evaluated based on VAS. After transferring mothers to recovery and stabilization of vital signs, the level of satisfaction with the quality of analgesia will be measured by numerical rating scale (NRS).
Participants/Inclusion and exclusion criteria
Inclusion criteria: pregnant mothers over 18 years with term pregnancy and single fetus and ASA class I or II, in the advanced stage of labor with cervical dilatation of at least 5 cm and tending to have painless labor Inclusion criteria: obesity, endocrine disease, drug abuse, allergy to study drugs and regional anesthesia contraindications
Intervention groups
In the bupivacaine-fentanyl group, 2.5 milligrams of bupivacaine (manufactured by Aspen Company) and 25 micrograms of fentanyl (manufactured by Darupakhsh Company,Iran) and in the bupivacaine-sufentanil group, 2.5 milligrams of bupivacaine and 2.5 micrograms of sufentanil (manufactured by Aburihan Company, Iran) will be injected.
Main outcome variables
Labor pain score and pregnant mothers' satisfaction with the quality of analgesia

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20230403057808N1
Registration date: 2023-04-19, 1402/01/30
Registration timing: prospective

Last update: 2023-04-19, 1402/01/30
Update count: 0
Registration date
2023-04-19, 1402/01/30
Registrant information
Name
Samaneh Ghazanfar Tehran
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 13 3336 9328
Email address
tehranisamaneh88rasht@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2023-04-21, 1402/02/01
Expected recruitment end date
2023-09-22, 1402/06/31
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Comparison of intrathecal injection of fentanyl and sufentanil along with bupivacaine in the onset, duration and quality of painless labor; A randomized double-blind clinical trial
Public title
Intrathecal injection of fentanyl and sufentanil along with bupivacaine in painless labor
Purpose
Supportive
Inclusion/Exclusion criteria
Inclusion criteria:
Primiparous or multiparous pregnant mothers with term pregnancy Single fetus American Society of Anesthesiologists' (ASA) classification I, II In the advanced stage of labor with cervical dilation at least 5 centimeter in Primiparous and at least 4 centimeter in multiparous mothers Age more than 18 years Tending to have painless labor
Exclusion criteria:
Refusal to participate in the study by pregnant mothers Obesity Endocrine disease Drug abuse Allergy to study drugs Regional anesthesia contraindications such as coagulopathy, high intracranial pressure and infection of injection site .
Age
From 18 years old
Gender
Female
Phase
3
Groups that have been masked
  • Participant
  • Investigator
  • Outcome assessor
Sample size
Target sample size: 80
Randomization (investigator's opinion)
Randomized
Randomization description
Eligible pregnant mothers who have given informed consent to participate in the study will be assigned to one of the two groups of bupivacaine with fentanyl and bupivacaine with sufentanil by an Anesthetist technician who is not involved in the study, with a random sequence in blocks of four created by computer (WinPepi software11.65), with the sequence of randomization blocks in a ratio of 1:1.Allocation concealment will be used for implementing the random sequence of participants in the study. So before assigning the person, the assigned group will not be This will prevent participants and researchers from knowing about the subsequent allocation. In order to maintain the random sequence, the outer surface of the envelopes is numbered in the same order. In order to maintain the random sequence, the outer surface of the envelopes will be numbered in the same order. At the time of registration of eligible patients for the study, one of the envelopes will be opened and the patient will be a candidate for one of the two methods of analgesia.
Blinding (investigator's opinion)
Double blinded
Blinding description
In order to double-blind the study, the anesthesiologist who prepares the study drug also performs the neuraxial block in order to take the necessary actions in case of side effects. Data collection will be done by the anesthesia assistant responsible for the project. In this study, the pregnant mother and the evaluator will be unaware of the type of drug used.
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Guilan University of Medical Sciences
Street address
Vice Chancellor for research, Shahid Siadati Avenue, Namjoo Street,Rasht
City
Rasht
Province
Guilan
Postal code
4144654839
Approval date
2023-03-01, 1401/12/10
Ethics committee reference number
IR.GUMS.REC.1401.598

Health conditions studied

1

Description of health condition studied
Intrathecal injection of fentanyl and sufentanil in combination with bupivacaine in onset, duration and quality of painless labor
ICD-10 code
O75.9
ICD-10 code description
Complication of labor and delivery, unspecified

Primary outcomes

1

Description
Mean time of onset of sensory block
Timepoint
At zero, 5, 10, 15, 30, 45, 60, 90, 120 and 150 minutes after injection
Method of measurement
Pinprick response in both lower limbs

2

Description
Mean time of duration of sensory block
Timepoint
At zero, 5, 10, 15, 30, 45, 60, 90, 120 and 150 minutes after injection
Method of measurement
Pinprick response in both lower limbs

3

Description
The state of motor block
Timepoint
At zero, 5, 10, 15, 30, 45, 60, 90, 120 and 150 minutes after injection
Method of measurement
Bromage test: zero (full flexion of knees and ankles), one (ability to move only knees), two (ability to move only legs), and three (inability to move knees and feet)

4

Description
Labor pain score
Timepoint
At zero, 5, 10, 15, 30, 45, 60, 90, 120 and 150 minutes after injection
Method of measurement
Based on visual analog scale as 1-10

5

Description
Satisfaction status of pregnant mothers with the quality of analgesia
Timepoint
After transferring pregnant mothers to recovery and stabilization of vital signs
Method of measurement
Numerical Rating (NRS) based on percentage

Secondary outcomes

1

Description
Drug complications: (Blood pressure drop more than 20% of baseline, itching, chills, nausea and vomiting, cases leading to cesarean section)
Timepoint
The duration of the procedure
Method of measurement
Observance

Intervention groups

1

Description
Intervention group1: In sterile conditions, a 25-size needle (B.Brown company)will be entered into the intraspinal space through lumbar vertebrae L3-L4 or L4-L5, and after ensuring the flow of cerebrospinal fluid, the injection will be performed. In the bupivacaine-fentanyl group, 2.5 milligrams of bupivacaine (manufactured by Aspen Company) will be injected with 25 micrograms of fentanyl (manufactured by Darupakhsh Company, Iran). The total volume of the solution is one milliliter.
Category
Treatment - Surgery

2

Description
Intervention group2 : In sterile conditions, a 25-size needle (B.Brown company)will be entered into the intraspinal space through lumbar vertebrae L3-L4 or L4-L5, and after ensuring the flow of cerebrospinal fluid, the injection will be performed. In the bupivacaine-sufentanil group, 2.5 milligrams of bupivacaine (manufactured by Aspen Company) will be injected along with 2.5 micrograms of sufentanil (manufactured by Aburihan Company, Iran). The total volume of the solution is one milliliter.
Category
Treatment - Surgery

Recruitment centers

1

Recruitment center
Name of recruitment center
Alzahra Hospital
Full name of responsible person
Dr.Samaneh Ghazanfar Tehran
Street address
Alzahra Hospital,Shahid Siadati Avenue, Namjoo Street,Rasht
City
Rasht
Province
Guilan
Postal code
4144654839
Phone
+98 13 3332 9524
Email
alzahra@gums.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Rasht University of Medical Sciences
Full name of responsible person
Dr Mohammadreza Naghipoor
Street address
Vice Chancellor for research, Shahid Siadati Avenue, Namjoo Street,Rasht
City
Rasht
Province
Guilan
Postal code
6694941446
Phone
+98 13 3333 5821
Email
naghi@gums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Rasht University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Rasht University of Medical Sciences
Full name of responsible person
Samaneh Ghazanfar Tehran
Position
assisstant professor, Anesthesiologist
Latest degree
Specialist
Other areas of specialty/work
Anesthesiology
Street address
Anesthesiology Research Center, Alzahra Hospital, Namjoo Street, Rasht, Iran
City
Rasht
Province
Guilan
Postal code
4144654839
Phone
+98 13 3332 9524
Email
Tehranisamaneh88rasht@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Rasht University of Medical Sciences
Full name of responsible person
Samaneh Ghazanfar Tehran
Position
assisstant professor, Anesthesiologist
Latest degree
Specialist
Other areas of specialty/work
Anesthesiology
Street address
Anesthesiology Research Center, Alzahra Hospital, Namjoo Street, Rasht, Iran
City
Rasht
Province
Guilan
Postal code
4144654839
Phone
+98 13 3332 9524
Email
Tehranisamaneh88rasht@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Rasht University of Medical Sciences
Full name of responsible person
Mohadese Ahmadi
Position
Research Expert/(MSc) English
Latest degree
Master
Other areas of specialty/work
Research Expert
Street address
Anestesiology Reseaech Center, Alzahra Hospital, Namjoo Street
City
Rasht
Province
Guilan
Postal code
4144654839
Phone
+98 13 3336 9328
Email
p.ahmadi2311@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Loading...